A s bstract. Protein Z was purified from human plasma by a four-step procedure which included barium citrate adsorption, ammonium sulfate fractionation, DEAE-Sepharose chromatography, and blue agarose chromatography with a yield of 20%. It is a 62,000 mol wt protein with an extinction coefficient of 12.0. The concentration of Protein Z in pooled, citrated plasma is 2.2 ug/ml and its half-life in patients starting warfarin anticoagulation therapy is estimated to be <2.5 d. The NH2-terminal sequence is Ala-Gly-Ser-Tyr-Leu-Leu-(Gla)-(Gla)-Leu-Phe-(Gla)-Gly-Asn-Leu. Neither Protein Z nor its cleavage products, which were obtained by treatment ofProtein Z with thrombin or plasmin, incorporated [3H]diisopropyl fluorophosphate. The physiological function of Protein Z remains unknown.
Introduction
Vitamin K is required for the posttranslational formation of a unique amino acid, gamma carboxyglutamic acid, which is present in a number of plasma proteins, including Factors II, VII, IX, X, Protein C, and Protein S, all of which play a role in hemostasis (1, 2) . The gamma carboxyglutamate residues appear to be essential to the functional properties of these proteins, mediating their binding to phospholipid surfaces via calcium bridges (3) . Recently Prowse and Esnouf described another vitamin K-dependent protein in bovine plasma and they named it Protein Z (4). Initially this protein was thought to represent a form of Factor X (single chain), but it was later identified as a discrete gamma carboxyglutamic acid-containing protein (5, 6) . The physiological function of bovine Protein Z remains unknown. Here we describe the purification and characterization ofa human plasma protein that appears to represent the human counterpart to bovine Protein Z.
ical Co. Human plasmas. Plasmas from patients with Factors V/VIII deficiency were gifts from Dr. Walter Kisiel (University of Washington, Seattle, WA-four patients) and Dr. Roger Edson (University of Minnesota, Minneapolis, MN-one patient).
Plasmas deficient in Factors II, V, VII, VIII, IX, X, XI, XII, and von Willebrands factor, and Passavoy trait plasma were obtained from George King Biomedical (Overland Park, KS), as was normal control plasma pooled from 20 donors. Individual normal control plasmas were obtained from laboratory personnel. Samples from eight patients starting warfarin therapy were taken from specimens sent to the Barnes Hospital hemostasis laboratory (St. Louis, MO).
Methods
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis was performed on 10% gels (ratio acrylamide/bis, 37.5:1) by the method of Laemmli (4% stacking gel) (7) or by the method of Weber (9) . The results were not corrected for losses due to hydrolysis. Half-cystine was determined as cysteic acid by the method of Hirs (10) .
The NH2-terminal sequence analysis of Protein Z was performed on a gas-phase sequenator (Applied Biosystems, Foster City, CA); phenylthiohydantoin derivatives were identified by high-performance liquid chromatography (1 1, 12) . Two separate analyses were performed using 1 nmol of Protein Z and gave identical results.
Extinction coefficient ofProtein Z Protein Z was dialyzed extensively into 0.1 M NaCl, 0.05 Tris, pH 7.5, and its extinction coefficient was determined by the method of Babul and Stellwagen (13) . No correction was made for light scattering.
Proteins
Human prothrombin, Factor X, Factor IX, and Factor VII were isolated as previously described (14, 15). Protein C was first purified from freshfrozen plasma by barium citrate adsorption, (NH4)2SO4 elution, and affinity chromatography using a murine monoclonal antibody, and then converted to activated Protein C with thrombin (16, 17) . Protein S was isolated by a procedure similar to that of Dahlbach, with the exception that DEAE Sepharose rather than DEAE Sephacel ion-exchange chromatography was used (18). Thrombin with a specific activity of 2.7 NIH units/ag was prepared from prothrombin (19) .
Human plasminogen was purified from fresh-frozen plasma by affinity chromatography on lysine-Sepharose; plasmin was prepared with urokinase linked to Sepharose 4B (20, 21 
Functional assays
Prothrombin, Factor VII, Factor IX, and Factor X were assayed as previously described (14, 15 1 ). We found, as noted by others for bovine Protein Z (4, 6) , that the use of an agarose-(as opposed to a dextran-) based ionexchange support was required for optimal separation of the Protein Z. The bars in Fig. 1 Characterization. The final preparation of Protein Z appeared to be homogeneous as judged by SDS-polyacrylamide gel electrophoresis (Fig. 2) . In the Laemmli discontinuous system (7), Protein Z frequently appeared as multiple, tightly spaced bands, and it migrated with an apparent molecular weight greater than that found when the continuous system of Weber and Osborne (8) was employed. When the latter method was used, Protein Z migrated as a single band with an apparent molecular weight of62,000, both before and after reduction. The extinction coefficient of Protein Z was estimated to be 12.0 using the method of Babul and Stellwagen (13) .
The amino acid composition of human Protein Z is shown in Table I , as is that previously published for bovine Protein Z (6) . The NH2-terminal amino acid sequence is shown in Table  II ; for comparison, those of human Factors II, VII, IX, X, Protein C, Protein S, and bovine Protein Z (25) (26) (27) (28) (29) (30) (31) are also shown. No amino acids were detected in cycles 7, 8, and 11, and these residues were assumed to represent gamma carboxyglutamic acids.
Plasma levels ofProtein Z. Heterologous rabbit anti-Protein Z antibodies were used to determine plasma levels of Protein Z by the rocket immunoelectrophoresis technique of Laurell. Normal citrated plasma pooled from 20 donors, when tested on 12 occasions, gave a Protein Z level of 2.2±0.14 ;g/ml (mean±standard deviation). The mean level of Protein Z in 10 individual normal donors was 2.2±0.4 with a range of 1.6 to 2.95 jig/ml.
Protein Z immunoelectrophoresis rockets could not be visualized (<0.2 sg/ml) by the third to fifth day after initiation of warfarin therapy in eight patients undergoing anticoagulant therapy for thromboembolic disease. Plasmas from five patients with Factor V/VIII deficiency and from one patient with Passavoy trait had normal levels of Protein Z, as did plasmas from patients with deficiencies of Factor II, V, VII, VIII, IX, X, XI, XII, or von Willebrands factor. (Fig. 2) . ZA was a single chain protein both reduced seen well in Fig. 2) 
